TennCare is continuing the process of reviewing all covered drug classes. Changes to the PDL (preferred drug list) may occur as new classes are reviewed, and previously reviewed classes are revisited. As a result of these changes, some medications your patients are now taking may be considered non-preferred agents in the future. Please inform your patients who are on these medications that switching to preferred products will decrease delays in receiving their medications. We encourage you to contact OptumRx’s Pharmacy Support Center (866-434-5520) or tnrxeducation@optum.com should you have additional questions. For more details on Clinical Criteria, please visit the website.
Also in Tennessee, the Tennessee Pharmacists Research and Education Foundation is looking to partner with 10 additional pharmacies for the Community Outreach Immunization Initiative. This opportunity is open to pharmacies across Tennessee that are willing to engage patients that have not received their COVID-19 vaccination series, as well as any other patients who may have gaps in their vaccination history. This opportunity will be a nine (9) month commitment and could earn your pharmacy up to $31,500. If you are interested register at the link here. If you have further questions about this opportunity, reach out to Danielle McCoy.
Finally in Tennessee, this communiqué has been sent to provide further clarification on the buprenorphine update changes that became effective May 15, 2023. Additionally, you will find an updated memo that properly reflects the recent buprenorphine changes for your records.
We encourage you to review this information thoroughly and contact the OptumRx Pharmacy Supports Center at 866-434-5520 or tnrxeducation@optum.com should you have questions.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.